SIBN — SI-BONE, Inc.

SI-BONE, Inc. Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: Total revenue for Q1 2026 was $52.6 million, reflecting an 11.2% year-over-year growth. U.S. revenue was $49.3 million (10% growth), while international revenue reached $3.3 million (34% growth).
• Gross Profit: Increased to $41.9 million, maintaining a gross margin of 79.8%.
• Operating Expenses: Grew by 4.1% to $47.0 million, resulting in a narrowed net loss of $4.3 million ($0.10 per diluted share), compared to a loss of $6.5 million in the prior year.
• Adjusted EBITDA: Improved to $2.5 million, a 440% increase from the previous year.
• Cash Position: Ended the quarter with $144.7 million in cash and marketable securities, with negative free cash flow of $3.4 million, a 50.7% improvement year-over-year.

2. Strategic Updates and Business Highlights

• Product Launches: Introduced Intra TI and TNT TORQ, expanding the product portfolio and targeting high-value clinical segments.
• Partnerships: Announced a collaboration with Smith & Nephew to enhance trauma market access.
• Physician Engagement: Active physicians increased to 1,650, a 17% growth, with ongoing efforts to deepen relationships and expand procedure types.
• Market Position: Positioned as a leader in sacroiliac joint and spinal pelvic fusion markets, with significant potential in pelvic trauma and interventional segments.

3. Forward Guidance and Outlook

• Revenue Guidance: Increased full-year revenue guidance to $230 million - $233 million, implying a growth rate of 14% to 16% year-over-year.
• Gross Margin: Raised expectations to approximately 79%, reflecting operational efficiencies and favorable procedure mix.
• Operating Expenses: Anticipated to grow by about 12.5% at the midpoint of revenue guidance, aligning with strategic investments for growth.

4. Bad News, Challenges, or Points of Concern

• Weather Impact: Q1 performance was slightly impacted by weather-related disruptions, estimated at around $500,000, though this is expected to be recaptured.
• Conservative Guidance Approach: The cautious increase in guidance reflects a disciplined approach, with management opting to grow into potential upside rather than overcommit.
• Cash Flow Variability: Expected higher variability in cash flow in the upcoming quarters due to timing of payments related to new headquarters buildout.

5. Notable Q&A Insights

• Weather Impact Clarification: Management noted that weather disruptions were minimal and that procedure rescheduling typically occurs within 60 days.
• Smith & Nephew Partnership: Anticipated revenue contributions from this partnership are expected to ramp up in the second half of 2026, with a total addressable market of approximately $300 million.
• New DRG Proposal: The proposed new DRG families for complex spinal fusion procedures could significantly enhance reimbursement rates, potentially increasing hospital payments by up to $50,000 per procedure.
• Future Growth Potential: Management expressed confidence in the potential for 2027 growth to exceed 2026, driven by ongoing product launches and favorable market dynamics.

Overall, SI-BONE, Inc. demonstrated solid financial performance in Q1 2026, with strategic initiatives aimed at expanding its market presence and enhancing physician engagement, while also navigating challenges related to market conditions and operational execution.